Published in Ther Drug Monit on January 01, 1988
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet (1999) 2.12
Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia (1997) 2.11
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis (2008) 1.69
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet (1986) 1.63
Debrisoquine hydroxylation polymorphism and personality. Lancet (1989) 1.62
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem (2001) 1.57
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry (1981) 1.52
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther (1993) 1.46
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet (1978) 1.42
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand (1998) 1.40
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol (1983) 1.33
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
The chemistry and kinetics of Lioresal. Postgrad Med J (1972) 1.29
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther (2008) 1.29
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28
Indole-3-acetic acid in human cerebrospinal fluid: identification and quantification by mass fragmentography. Science (1972) 1.27
Methylation of mercury compounds by methylcobalamin. Biochemistry (1971) 1.27
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26
"Serotonin depression"--a biochemical subgroup within the affective disorders? Science (1976) 1.24
Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man. Eur J Clin Pharmacol (1977) 1.22
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 1.20
Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia (2000) 1.17
Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther (2011) 1.15
Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981) 1.14
Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology (2008) 1.14
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis (2004) 1.14
Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia (2002) 1.14
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr (2002) 1.12
Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol Suppl (1978) 1.12
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther (1998) 1.12
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12
Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther (1998) 1.11
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11
The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol (1983) 1.11
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol (1990) 1.11
Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol (1991) 1.10
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics (1999) 1.09
Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther (1998) 1.08
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer (1999) 1.08
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit (1994) 1.05
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry (1995) 1.05
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther (2007) 1.05
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol (1997) 1.05
Gallstones, cholecystectomy, and duodenogastric reflux of bile acid. Scand J Gastroenterol (1986) 1.04
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther (1997) 1.03
Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin Pharmacol Ther (1973) 1.03
Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS (1999) 1.03
Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet (1985) 1.03
High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.03
Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol (1997) 1.02
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther (1989) 1.02
Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther (1983) 1.01
Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia (2001) 1.00
Nonconvulsive status epilepticus: high incidence of complex partial status. Epilepsia (1986) 1.00
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther (1996) 1.00
Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1997) 1.00
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol (2008) 1.00
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit (1992) 1.00
Metabolism of niridazole in various species, including man. Ann N Y Acad Sci (1969) 0.99
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand (1993) 0.99
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics (1996) 0.99
Valpromide/carbamazepine and risk of teratogenicity. Lancet (1985) 0.99
Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol (1984) 0.99
The metabolism of 14C-oxcarbazepine in man. Xenobiotica (1986) 0.99
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol (1986) 0.98
Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res (1999) 0.98
Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol (1984) 0.97
Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther (1980) 0.97
Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci (1979) 0.97